Skip to main content
Midas Edge

Bone Biologics Corp

For the period ended Sep 30, 2026. Filed Oct 26, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 26, 2026

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statement of Stockholders’ Equity (Unaudited)

Condensed Consolidated Statement of Stockholders’ Equity

For the Nine Months ended September 30, 2026

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
SharesAmountCapitalDeficitEquity
Balance at December 31, 20251,795,260$1,795$93,506,122$(88,130,369)$5,377,548
Fair value of vested stock options--23,505-23,505
Options issued to settle accrued bonus--34,854-34,854
Net loss---(765,988)(765,988)
Balance at March 31, 20261,795,2601,79593,564,481(88,896,357)4,669,919
Fair value of vested stock options--8,253-8,253
Issuance of common shares from ATM, net of costs of $2,09015,1201520,165-20,180
Net loss---(773,702)(773,702)
Balance at June 30, 20261,810,3801,81093,592,899(89,670,059)3,924,650
Fair value of vested stock options--3,425-3,425
Issuance of pre-funded warrants and warrants in private placement, net of costs of $358,221--2,639,667-2,639,667
Exercise of pre-funded warrants1,578,6771,579--1,579
Net loss---(617,651)(617,651)
Balance at September 30, 20263,389,057$3,389$96,235,991$(90,287,710)$5,951,670

Condensed Consolidated Statement of Stockholders’ Equity

For the Nine Months ended September 30, 2025

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
SharesAmountCapitalDeficitEquity
Balance at December 31, 2024492,417$492$88,504,543$(85,021,378)$3,483,657
Fair value of vested stock options--50,605-50,605
Options issued to settle accrued bonus--46,183-46,183
Issuance of common shares from ATM, net of costs of $13,02952,84353347,496-347,549
Net loss---(1,017,092)(1,017,092)
Balance at March 31, 2025545,26054588,948,827(86,038,470)2,910,902
Fair value of vested stock options--72,899-72,899
Proceeds from sale of common stock , pre-funded warrants and warrants in public offering, net of offering costs of $647,208793,7507944,351,998-4,352,792
Exercise of pre-funded warrants346,250346(346)--
Net loss---(740,519)(740,519)
Balance at June 30, 20251,685,2601,68593,373,378(86,778,989)6,596,074
Fair value of vested stock options--87,180-87,180
Exercise of pre-funded warrants110,000110(110)--
Net loss---(666,737)(666,737)
Balance at September 30, 20251,795,260$1,795$93,460,448$(87,445,726)$6,016,517
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.